Almirall is a global biopharmaceutical company focused on medical dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis or acne. We care and listen to our patients’ needs. We find solutions for them. We aim to empower them. Almirall has 1 R&D center, 2 chemical plants and 2 pharmaceutical plants. Our more than 1,900 employees make it possible for our treatments to be available in over 100 countries across 5 continents, through our 15 global affiliates and via a strategic partnership network. Almirall is listed on the Spanish Stock Exchange (ticker: ALM).
市場タイムラインとシグナルフィードを解放
過去 90 日間に 39 件のシグナル。
この企業が各市場へ参入した順序 — 古い順から新しい順へ
14 active postings
Facharztaußendienst Dermatologie (Biologika) (m/w/d), Region L1: Dresden, Cottbus, Görlitz, Wittenberg
登録してシグナルフィードをすべて表示
Almirall の海外展開を競合と比較
Almirall自社バーは比較対象企業間の相対的な規模を示します。
列5| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
 Almirall自社 | 3 | 0 | +38% | 38 | 30 |
Product Manager (m/w/d) Atopic Dermatitis (AD)
求人を見るHamburg, Hamburg, Germany · 3日前
MEDICAL AFFAIRS SENIOR MANAGER Temporary
求人を見るBarcelona, Catalonia, Spain · 4日前
IT BUSINESS PROCESS MANAGER
求人を見るSant Andreu de la Barca, Catalonia, Spain · 6日前
At Almirall, our "Act4Impact" strategy is the blueprint that integrates five vital pillars into our daily operations. This framework ensures our growth in medical dermatology is as responsible as it is innovative. Our commitment to a positive legacy includes: - Planet: A science-led roadmap toward Net Zero emissions. -People: Fostering a diverse and inclusive culture where our teams lead with integrity. - Patients: Placing people living with skin conditions at the core of every decision. - Part ...
終了For those living with chronic skin conditions, physical symptoms are only one part of the journey. Psychological distress, social isolation, and sleep disturbances can persist even after skin clearance. At Almirall, we aim to lead a paradigm shift. By integrating the WHO-5 Well-being Index into our clinical trials, we demonstrate our commitment to placing patient wellbeing at the heart of everything we do. Our goal is to transform the patient's world - addressing the person that lives behind the ...
終了For those living with chronic skin conditions, physical symptoms are only one part of the journey. Psychological distress, social isolation, and sleep disturbances can persist even after skin clearance. At Almirall, we aim to lead a paradigm shift. By integrating the WHO-5 Well-being Index into our clinical trials, we demonstrate our commitment to placing patient wellbeing at the heart of everything we do. Our goal is to transform the patient's world - addressing the person that lives behind the ...
終了Almirallの株主総会でCarlos GallardoがCEO、Enrique de Leyvaが副社長に再選。1株当たり0.19ユーロの柔軟な配当を実施予定。
Almirallの株主総会がカルロス・ガヤルドを社長兼CEOに再選し、1株当たり0.19ユーロの柔軟な配当を承認。
Qualifyzeが品質洞察プラットフォームを導入。世界最大の監査データベースを活用したAI駆動の製薬リスク管理ツール。
認証済みメールと直通電話を解放
無料 · カード不要
Almirall の事業、市場、成長シグナルに関する簡潔な回答。
© 2026 Pubrio. 無断転載を禁じます。
